Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Dec 19;75(12):2281-2282.
doi: 10.1093/cid/ciac667.

Statin Needs to be Continued During Paxlovid Therapy in COVID-19

Alpo Vuorio  1   2 , Petri T Kovanen  3 , Frederick Raal  4
Affiliations
Editorial

Statin Needs to be Continued During Paxlovid Therapy in COVID-19

Alpo Vuorio et al. Clin Infect Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. A. V. reports support for attending meetings and/or travel for European Atherosclerosis Society (EAS) (EAS paid flight tickets and accommodation); and role as unpaid member of the editing team Finnish Current Guidelines in Dyslipidemia. P. T. K. has received consultancy fees, lecture honoraria, and/or travel fees from Amgen, Novartis, Raisio Group, and Sanofi. F. R. has received research grants, honoraria, or consulting fees for professional input and/or lectures from Sanofi, Regeneron, Amgen, and Novartis, and is a board member of the International Atherosclerosis Society, unpaid. The other author reports no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Comment in

Comment on

References

    1. Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis 2022:ciac443. - PMC - PubMed
    1. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies . 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in Atherosclerosis. 2020 Feb; 294:80–82]. Atherosclerosis 2019; 290:140–205. - PubMed
    1. Vuorio A, Kovanen PT, Raal F. Cholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid therapy. Future Virol 2022. In press. - PMC - PubMed
    1. Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, et al. Investigating lipid-modulating agents for prevention or treatment of COVID-19: JACC state-of-the-art review. J Am Coll Cardiol 2021; 78:1635–54. - PMC - PubMed
    1. Vuorio A, Strandberg TE, Raal F, Santos RD, Kovanen PT. Familial hypercholesterolemia and COVID-19: a menacing but treatable vasculopathic condition. Atheroscler Plus 2021; 43:3–6. - PMC - PubMed

Substances

LinkOut - more resources